Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Condition:   Squamous Cell Carcinoma of the Head and Neck
Interventions:   Drug: [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.;   Drug: [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.
Sponsors:   CellSight Tehnologies, Inc.;   Stanford University
Not yet recruiting - verified April 2017

http://ift.tt/2pmfwdV